Altimmune Inc (ALT) 13F Holdings Overview (Q2 2026)

ALT ranks #2877 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

212 institutions disclose a position in ALT, but none treat it as a major bet — even Trails Edge Capital Partners, LP, its most concentrated holder, allocates just 1.3% of its own portfolio to it.

Vontobel Holding Ltd. has added to its ALT position for two straight quarters, increasing it by $26.5K to reach $88.1K today.

Summit Financial Wealth Advisors, LLC has trimmed its ALT position for two straight quarters, cutting it by $22.7K while still holding $295.4K.

ALT is down 6.8% today, but institutions show net buying of $262.4M this quarter — a divergence between today's price move and the underlying institutional flow.

ALT reported a net loss of $91.8M over the trailing twelve months.

• Not yet profitable — net loss of $91.8M over the trailing twelve months
• Revenue grew 105.0% year over year
• Net income declined year over year, from -$87.7M to -$91.8M
• Operating cash flow was negative, using $67.5M in cash
• Current ratio of 18.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.24x equity — within a conventional range